Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Consuelo Amantini
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Consuelo Amantini wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival. 2019

Amantini, Consuelo / Morelli, Maria Beatrice / Nabissi, Massimo / Piva, Francesco / Marinelli, Oliviero / Maggi, Federica / Bianchi, Francesca / Bittoni, Alessandro / Berardi, Rossana / Giampieri, Riccardo / Santoni, Giorgio. ·School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy. · School of Pharmacy, Experimental Medicine Section, University of Camerino, Camerino, Italy. · Department of Specialistic Clinical and Odontostomatological Sciences, Polytechnic University of Marche, Ancona, Italy. · Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. · Oncology Clinic, AOU Ospedali Riuniti, Polytechnic University of Marche, Ancona, Italy. ·Front Oncol · Pubmed #31552188.

ABSTRACT: The interest in liquid biopsy is growing because it could represent a non-invasive prognostic or predictive tool for clinical outcome in patients with pancreatic ductal adenocarcinoma (PDAC), an aggressive and lethal disease. In this pilot study, circulating tumor cells (CTCs), CD16 positive atypical CTCs, and CTC clusters were captured and characterized in the blood of patients with PDAC before and after palliative first line chemotherapy by ScreenCell device, immunohistochemistry, and confocal microscopy analysis. Gene profiles were performed by digital droplet PCR in isolated CTCs, five primary PDAC tissues, and three different batches of RNA from normal human pancreatic tissue. Welsh's

2 Article Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. 2019

Giampieri, Riccardo / Piva, Francesco / Occhipinti, Giulia / Bittoni, Alessandro / Righetti, Alessandra / Pagliaretta, Silvia / Murrone, Alberto / Bianchi, Francesca / Amantini, Consuelo / Giulietti, Matteo / Ricci, Giulia / Principato, Giovanni / Santoni, Giorgio / Berardi, Rossana / Cascinu, Stefano. ·Oncologia Clinica c/o Università Politecnica delle Marche, Dipartimento Scienze Cliniche e Molecolari - Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Ancona, Italy. · Biologia e biochimica c/o Università Politecnica delle Marche, Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche - Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Ancona, Italy. · Farmacia, Università di Camerino, Camerino, Italy. · Dipartimento Onco-ematologia Ospedale Universitario di Modena, Università di Modena e Reggio Emilia, Modena, Italy. ·PLoS One · Pubmed #31048929.

ABSTRACT: INTRODUCTION: Pancreatic ductal adenocarcinoma is associated to dismal prognosis despite the use of palliative chemotherapy, partly due to the lack of knowledge of biological processes underlying disease progression. Exosomes have been identified as biomarkers sources in different cancer types. Aim of the study was to analyse the contents of circulating exosomes in patients with pancreatic cancer who received palliative chemotherapy. PATIENTS AND METHODS: Patients were submitted to blood sample collection before chemotherapy (T0) and after 3 months (T3). We quantified by an ELISA-based technique specific proteins of cancer-derived exosomes (CD44,CD44v6,EpCAM,CD9,CD81,Tspan8,Integrin α6,Integrin β4,CD24,CXCR4). We correlated the baseline levels of these factors and changes between T3 and T0 and survival outcomes. Survival analyses were performed by Kaplan-Meier method. Correlation was assessed by log-rank test and level of statistical significance was set at 0.05. Multivariate analysis was performed by logistic regression analysis. RESULTS: Nineteen patients were enrolled. EpCAM T0 levels and increased EpCAM levels from T0 to T3 were those mostly associated with differences in survival. Patients having higher EpCAM had median progression free survival (PFS) of 3.18vs7.31 months (HR:2.82,95%CI:1.03-7.73,p = 0.01). Overall survival (OS) was shorter for patients having higher EpCAM (5.83vs16.45 months,HR:6.16,95%CI:1.93-19.58,p = 0.0001) and also response rates (RR) were worse (20%vs87%,p = 0.015). EpCAM increase during treatment was associated with better median PFS (2.88vs7.31 months,HR:0.24,95%CI:0.04-1.22,p = 0.003). OS was also better (8.75vs11.04 months, HR:0.77,95%CI:0.21-2.73,p = 0.66) and RR were 60%vs20% (p = 0.28). Among clinical factors that might determine changes on PFS and OS, only ECOG PS was associated to significantly worse PFS and OS (p = 0.0137and<0.001 respectively).Multivariate analysis confirmed EpCAM T0 levels and EpCAM T0/T3 changes as independent prognostic factors for PFS. CONCLUSIONS: Pancreatic cancer patients exosomes express EpCAM, whose levels change during treatment. This represents a useful prognostic factor and also suggests that future treatment modalities who target EpCAM should be tested in pancreatic cancer patients selected by exosome EpCAM expression.